United States · Series B startup
Funding summaryUpdated 26 Oct 2026
$113Mraised across 2 rounds since 2017, from 2 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
venBio PartnersLead
Nextech InvestLead
Google Ventures
Canaan
Google
Alexandria Real Estate Equities
Omega Funds
Osage University Partners
Pfizer
WuXi AppTecReported by FinSMEsSEC filing: $15M sold, first sale Apr 2019
Osage University PartnersPfizerReported by FinSMEsSEC filing: $13M sold, first sale Feb 2017
From Arrakis Therapeutics's own website and the SEC filings it signed: 3 on the team.
On the board, as filediColleen CuffaroJakob LovenNikola TrbovicRaj ParekhRichard Gaster
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Missing a round, or an investor who was in one? Tell us.
Arrakis Therapeutics's investors include Osage University Partners, Pfizer, Celgene, Henri Termeer and venBio Partners, and 10 more on record. venBio Partners led its latest round.
Arrakis Therapeutics has raised $113M across 2 rounds since 2017.
Arrakis Therapeutics's most recent round was a Series B of $75M in Apr 2019, led by venBio Partners.
Its most recent round, $75M in Apr 2019, is also its largest on record.
Arrakis Therapeutics's first round on record, in Feb 2017, was backed by Osage University Partners, Pfizer and Celgene and 2 others.
Arrakis Therapeutics's latest named round is a Series B, in Apr 2019.
Arrakis Therapeutics is based in the United States.
venBio Partners led the Series B in 2019.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
